LERIBANE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LERIBANE (LERIBANE).
Leribane is a synthetic cannabinoid receptor agonist with high affinity for CB1 and CB2 receptors. It inhibits adenylate cyclase activity via Gi/o protein coupling, leading to decreased cAMP accumulation, modulation of ion channels, and inhibition of neurotransmitter release.
| Metabolism | Primarily hepatic via CYP3A4 and CYP2C9 isoenzymes; undergoes hydroxylation and glucuronidation; minor contribution from CYP2D6. |
| Excretion | Renal: 70% unchanged; biliary/fecal: 30% as metabolites |
| Half-life | 24 hours (range 20-30 h); accumulates to steady state in ~5 days, requires dose adjustment in renal impairment |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 8-12 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 60-70% (first-pass metabolism); Intravenous: 100% |
| Onset of Action | Oral: 2-4 hours; Intravenous: within 30 minutes |
| Duration of Action | 24-36 hours; clinical effect may persist beyond half-life due to tissue binding |
| Molecular Weight | 362.85 |
5-10 mg orally twice daily; maximum 30 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-59 mL/min: 5 mg twice daily; GFR 15-29 mL/min: 5 mg once daily; GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: 5 mg twice daily; Child-Pugh B: 5 mg once daily; Child-Pugh C: contraindicated. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Initiate at 5 mg once daily; titrate cautiously due to increased risk of adverse effects; maximum 15 mg/day. |
| 1st trimester | Limited data; animal studies show developmental toxicity. Avoid unless maternal benefit outweighs risk. |
| 2nd trimester | Limited data; potential risk of fetal growth restriction. Use only if clearly needed. |
| 3rd trimester | May cause neonatal respiratory depression if used near term. Avoid during labor and delivery. |
Clinical note
Comprehensive clinical and safety monograph for LERIBANE (LERIBANE).
| Placental transfer | Crosses placenta; detected in fetal plasma at 50-100% of maternal levels. |
| Breastfeeding | Excretion into breast milk is probable (lipid-soluble, low molecular weight). Avoid breastfeeding due to risk of CNS depression in the infant. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to leribaneSevere hepatic impairmentNarrow-angle glaucoma
| Precautions | Central nervous system depression (may impair cognition and motor skills); risk of psychiatric adverse effects (anxiety, paranoia, psychosis); potential for dependence and withdrawal; serotonin syndrome when combined with serotonergic drugs; hepatotoxicity at high doses; cardiovascular effects (tachycardia, hypertension). |
| Food/Dietary | No significant food interactions. However, taking with food may slightly reduce absorption rate, but overall efficacy is unaffected. Avoid grapefruit juice as it may alter drug metabolism (potential CYP3A4 interaction). |
Loading safety data…
| L5 |
| Teratogenic Risk | First trimester: Risk of congenital malformations based on animal studies, including neural tube defects and cardiac anomalies. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to possible uteroplacental insufficiency. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, liver function, and renal function regularly. Fetal ultrasound for growth and amniotic fluid volume every 4 weeks. Nonstress test weekly after 32 weeks. |
| Fertility Effects | No specific data on fertility impairment observed in animal studies. However, may affect reproductive function in women of childbearing potential; advise contraception during therapy. |
| Clinical Pearls |
| LEVOCETIRIZINE, an antihistamine, may cause sedation; avoid driving after dosing. Adjust dose in renal impairment (CrCl <50 mL/min: 2.5 mg every other day). Onset of action is 1-2 hours; duration ~24 hours. |
| Patient Advice | Take once daily as prescribed, usually in the evening to minimize daytime drowsiness. · Avoid alcohol and other CNS depressants as they may increase sedation. · Do not exceed recommended dose; overuse can cause dry mouth, dizziness, or somnolence. · Inform your doctor if you have liver or kidney disease, urinary retention, or glaucoma. · If you are pregnant, planning to become pregnant, or breastfeeding, consult your healthcare provider before use. |